Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

(2017) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

(2016) Ivan S. Moiseev et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

(2016) M. Mielcarek et al.   BLOOD

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

(2016) Nicolaus Kröger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen–Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease

(2015) Kenneth F. Bradstock et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies

(2015) Amin M. Alousi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission

(2015) A Ruggeri et al.   BONE MARROW TRANSPLANTATION

OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation

(2015) Udo Holtick et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

(2014) C. G. Kanakry et al.   BLOOD

Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

(2014) M. Boyiadzis et al.   CLINICAL CANCER RESEARCH

Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

(2014) Christopher G. Kanakry et al.   JOURNAL OF CLINICAL ONCOLOGY

Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide

(2013) C. G. Kanakry et al.   Science Translational Medicine

Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies

(2012) P. Di Bartolomeo et al.   BLOOD

Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation

(2012) Leo Luznik et al.   SEMINARS IN ONCOLOGY

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

(2011) M. Jagasia et al.   BLOOD

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

(2010) L. Luznik et al.   BLOOD

Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

(2010) Ted A. Gooley et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION